Brokerages expect that OrthoPediatrics Corp. (NASDAQ:KIDS) will post ($0.23) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for OrthoPediatrics’ earnings, with the highest EPS estimate coming in at ($0.12) and the lowest estimate coming in at ($0.34). OrthoPediatrics posted earnings of ($0.30) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 23.3%. The business is scheduled to issue its next quarterly earnings results on Tuesday, May 4th.
According to Zacks, analysts expect that OrthoPediatrics will report full year earnings of ($0.73) per share for the current financial year, with EPS estimates ranging from ($1.02) to ($0.37). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.47) per share, with EPS estimates ranging from ($0.69) to ($0.18). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover OrthoPediatrics.
OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Thursday, March 11th. The company reported ($0.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.46). OrthoPediatrics had a negative net margin of 34.26% and a negative return on equity of 11.57%.
Several analysts have commented on the company. Zacks Investment Research downgraded OrthoPediatrics from a “hold” rating to a “sell” rating in a research note on Friday, March 12th. Piper Sandler boosted their target price on OrthoPediatrics from $55.00 to $62.00 in a research report on Tuesday, April 6th. One investment analyst has rated the stock with a sell rating and three have given a buy rating to the company. OrthoPediatrics has a consensus rating of “Buy” and an average target price of $54.50.
KIDS traded down $0.03 on Wednesday, hitting $49.52. 1,617 shares of the company traded hands, compared to its average volume of 207,530. The company has a 50 day moving average of $50.09 and a 200-day moving average of $46.76. The stock has a market capitalization of $973.46 million, a PE ratio of -34.37 and a beta of 0.67. OrthoPediatrics has a 12-month low of $38.01 and a 12-month high of $57.42.
In related news, Director Bernie B. Berry III sold 699 shares of the company’s stock in a transaction that occurred on Thursday, February 25th. The stock was sold at an average price of $57.00, for a total value of $39,843.00. Following the sale, the director now owns 32,481 shares in the company, valued at approximately $1,851,417. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bernie B. Berry III sold 3,136 shares of the company’s stock in a transaction that occurred on Wednesday, January 27th. The stock was sold at an average price of $51.73, for a total value of $162,225.28. Following the completion of the sale, the director now owns 40,481 shares in the company, valued at approximately $2,094,082.13. The disclosure for this sale can be found here. Insiders have sold a total of 47,686 shares of company stock worth $2,589,408 in the last quarter. 33.60% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in KIDS. Group One Trading L.P. acquired a new stake in shares of OrthoPediatrics in the 4th quarter worth approximately $58,000. Strs Ohio acquired a new stake in shares of OrthoPediatrics in the 3rd quarter worth approximately $123,000. Jane Street Group LLC acquired a new stake in shares of OrthoPediatrics in the 4th quarter worth approximately $201,000. Tudor Investment Corp Et Al acquired a new stake in shares of OrthoPediatrics in the 4th quarter worth approximately $218,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of OrthoPediatrics by 21.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,942 shares of the company’s stock worth $230,000 after acquiring an additional 866 shares during the period. Institutional investors and hedge funds own 71.74% of the company’s stock.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
Featured Story: What does cost of debt say about a company’s financial health?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.